Dihydropyridine
or DHP is arterial-specific vasodilators of peripheral resistance arteries that
causes generalized vasodilation, including the intestinal, renal, cerebral, and
coronary vascular beds. It is often called calcium-channel agonists and calcium-channel
activators. It is particularly well known in pharmacology as L-type calcium
channel blockers, which is used in the treatment of hypertension. It has high
vascular selectivity thus it is primarily employed to control the vascular
resistance and arterial pressure. It includes various drugs such as Cilnidipine,
Amlodipine (Norvasc), Felodipine (Plendil), Verapamil (Calan, Isoptin, Covera, Verelan),
Nicardipine (Cardene), Nisoldipine, Diltiazem (Cardizem, Tiazac, Dilacor),
Isradipine, Nifedipine (Procardia, Adalat) and others. All these drugs are very
easy to identify as its drug names end with ‘pine’. These drugs cause noteworthy
dilation of blood vessels & relatively little effect on the heart muscle or
heart rate. They are most beneficial for treating hypertension. Amlodipine drug
holds major share in market owing to rise in preference by the physician or
consultant towards amlodipine over the other drugs. Common side effects of
dihydropyridine group of calcium channel blockers include dizziness, flushing, headache,
and foot & ankle swelling. The most common side effect of both diltiazem
and verapamil is constipation, which can occur in up to 25 percentage of people
treated with these drugs.
According to study, “Global
Dihydropyridine Market Status (2015-2019) and Forecast (2020-2024) by Region,
Product Type & End-Use” the key companies operating in the
global dihydropyridine market are Shenzhen Simeiquan Biotechnology Co. Ltd.,
Weifang Union Biochemistry Co., Ltd., Boc Sciences, Yuyao Tuqiang Chemical Co.,
Ltd., Angene International Limited, Skyrun Industrial Co., Ltd., Triveni
Chemicals, Haihang Industry Co., Ltd., Neostar United Industrial Co., Ltd.
Based on type, dihydropyridine market is
segmented into purity 98%, purity 99% and other. Based on distribution channel,
market is segmented into retail pharmacies, hospitals and others. Based on
treatment, market is segmented into hypertension, anti-obesity, angina
pectoris, pregnancy, and others. Hypertension often referred as an elevated
blood pressure, which is one of the major causes
associated with heart diseases. In addition, based on application, market is
segmented into veterinary drugs, pharmaceutical and others.
The dihydropyridine
market is driven by growth in expansion of the pharmaceutical industry,
followed by easy availability of drugs at low cost and increase in research
& development (R&D) activities related to cardiovascular diseases.
However, side-effects associated with dihydropyridine such as headache etc. may
impact the market. Moreover, rise in percentage of the obese population is a
key opportunity for market.
Based on geography, the North-American region
dominates the dihydropyridine market
owing to rise in concern over diseases related to obesity and increase in the
geriatric population in the region. Whereas, the European and Asian-Pacific
regions are expected to exhibit substantial growth rate due to change in
lifestyle and rise in obesity among the young population leads to hypertension or
anxiety disorders over the forecast period. In upcoming years, it is predicted
that future of the market will be bright on account of growth in demand from
pharmaceutical industry during the forecast period.
For More Information, refer to below link:-
Related Report:-
Contact
Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
